ICER Expands Drug Value Comparison Program
This article was originally published in The Pink Sheet Daily
The non-profit Institute for Clinical and Economic Review plans comparative value and price assessments for up to 20 new drugs over the next two years, supported by grant funding.
You may also be interested in...
Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.
Bills to narrow the Medicare price negotiation program’s reach generated extensive discussion at the hearing.
As further details emerge, questions continue about whether the CMMI model could delay access to Lyfgenia and Casgevy; states will be added on ‘rolling basis.’ A new administration could change or cancel the model, but a CMS official predicts that is unlikely.